Residual inflammation in the cerebrospinal fluid after short- and long-term natalizumab treatment in relapsing-remitting multiple sclerosis - Poll - MDSpire

Persistent Inflammation in Cerebrospinal Fluid Following Short- and Long-Term Treatment with Natalizumab in Patients with Relapsing-Remitting Multiple Sclerosis

  • By

  • Sophie Buhelt

  • Malene Bredahl Hansen

  • Helle Bach Søndergaard

  • Sahla El Mahdaoui

  • Marie Mathilde Hansen

  • Mie Reith Mahler

  • Jeppe Romme Christensen

  • Finn Sellebjerg

  • June 5, 2026

Share

Original Source(s)

Residual inflammation in the cerebrospinal fluid after short- and long-term natalizumab treatment in relapsing-remitting multiple sclerosis

  • by Sophie Buhelt, Malene Bredahl Hansen, Helle Bach Søndergaard, Sahla El Mahdaoui, Marie Mathilde Hansen, Mie Reith Mahler, Jeppe Romme Christensen, Finn Sellebjerg

  • June 5, 2026

Related Content

Editorial: Immune functions of neuroglia

A convergence of global epidemics: diabetes as a modulator of neurodegenerative and neuro-inflammatory disorders

Donor-specific pathological features associate with genetic background, lesion type distribution, and clinical heterogeneity in multiple sclerosis